#751
|
|||
|
|||
Ââîäèòñÿ íîâàÿ êàòåãîðèÿ ñåðäå÷íî-ñîñóäèñòîãî ðèñêà (Extreme risk) è áîëåå íèçêèå öåëè ëå÷åíèÿ ÕÑ ËÏÍÏ < 55 ìã/äë (< 1,42 ììîëü/ë)
2017 AACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease: Objectives and Structure [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#752
|
|||
|
|||
 Ðîññèè ïåðåñìîòðåíû öåëåâûå óðîâíè ÕÑ ËÏÍÏ î÷åíü âûñîêîãî è âûñîêîãî ðèñêà Äèàãíîñòèêà è êîððåêöèÿ íàðóøåíèé ëèïèäíîãî îáìåíà ñ öåëüþ ïðîôèëàêòèêè è ëå÷åíèÿ àòåðîñêëåðîçà Ðîññèéñêèå ðåêîìåíäàöèè 2017 ãîäà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#753
|
|||
|
|||
Ðîññèéñêèå ðåêîìåíäàöèè ïî äèàãíîñòèêå è ëå÷åíèþ ñåìåéíîé ãèïåðõîëåñòåðèíåìèè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#754
|
|||
|
|||
2017 Focused update on Dual Antiplatelet Therapy (DAPT)
ESC Clinical Practice Guidelines [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of) ESC Clinical Practice Guidelines [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì |
#755
|
|||
|
|||
[center]Äåôèöèò æåëåçà è àíåìèÿ ýòî ðàçíûå ñîñòîÿíèÿ ïðè ñåðäå÷íîé íåäîñòàòî÷íîñòè?
Iron Deficiency and Anemia in Heart Failure [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#756
|
|||
|
|||
Èíúåêöèè êàíàêèíóìàáà (ìîíîêëîíàëüíûå àíòèòåëà ê èíòåðëåéêèíó-1β) ïàöèåíòàì ñ ÎÈÌ â àíàìíåçå, èìåþùèì òàêæå óðîâåíü hs-CPR 2 ìã/ë è âûøå ñíèçèëè ïåðâè÷íóþ êîíå÷íóþ òî÷êó (íåôàòàëüíûå ÎÈÌ, íåôàòàëüíûå ÎÍÌÊ è ñåðäå÷íî-ñîñóäèñòóþ ñìåðòíîñòü) ïðèìåðíî çà 4 ãîäà íà 15% (â ãðóïïå äîçû 150 ìã êàæäûå 3 ìåñ.). Òåðàïèÿ ïðîâîäèëàñü â äîïîëíåíèå ê ñîâðåìåííîé ðåêîìåíäîâàííîé ãàéäëàéíàìè (â ò. ÷. àíòèàãðåãàíòû, ñòàòèíû), ìåäèàííûé óðîâåíü ËÏÍÏ "íà âõîäå" áûë 2,13 ììîëü/ë.) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
#757
|
||||
|
||||
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
Ñèíóñîâûé ðèòì âñå-òàêè ëó÷øå, òîëüêî óäåðæèâàòü åãî íóæíî íå ÿäàìè.
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |
#758
|
||||
|
||||
NOAC, medication and bleeding in NVAF
Among 91 330 patients with nonvalvular atrial fibrillation (mean age, 74.7 years [SD, 10.8]; men, 55.8%; NOAC exposure: dabigatran, 45 347 patients; rivaroxaban, 54 006 patients; and apixaban, 12 886 patients), 4770 major bleeding events occurred during 447 037 person-quarters with NOAC prescriptions. The most common medications co-prescribed with NOACs over all person-quarters were atorvastatin (27.6%), diltiazem (22.7%), digoxin (22.5%), and amiodarone (21.1%).
Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NOACs had a significant increase in adjusted incidence rates per 1000 person-years of major bleeding than NOACs alone: 38.09 for NOAC use alone vs 52.04 for amiodarone (difference, 13.94 [99% CI, 9.76-18.13]); 102.77 for NOAC use alone vs 241.92 for fluconazole (difference, 138.46 [99% CI, 80.96-195.97]); 65.66 for NOAC use alone vs 103.14 for rifampin (difference, 36.90 [99% CI, 1.59-72.22); and 56.07 for NOAC use alone vs 108.52 for phenytoin (difference, 52.31 [99% CI, 32.18-72.44]; P < .01 for all comparisons). Compared with NOAC use alone, the adjusted incidence rate for major bleeding was significantly lower for concurrent use of atorvastatin, digoxin, and erythromycin or clarithromycin and was not significantly different for concurrent use of verapamil; diltiazem; cyclosporine; ketoconazole, itraconazole, voriconazole, or posaconazole; and dronedarone. --- JAMA. 2017 Oct 3;318(13):1250-1259. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#760
|
||||
|
||||
Âòîðûå ñóòêè â íàö. íîâîñòÿõ äàæå ïî òåëåâèäåíèþ:
Just Released—The 2017 Hypertension Clinical Practice Guidelines [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#761
|
||||
|
||||
Åñëè õî÷åøü áûòü çäîðîâ - ïðîñâåùàéñÿ,
ïîçàáóäü ïðî äîêòîðîâ - êîôå íàñëàæäàéñÿ. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#762
|
||||
|
||||
×òî äåëàþò, åñëè ïàöèåíòû æàëóþòñÿ íà ìèàëãèè ïðè ïðèåìå ñòàòèíîâ â ÑØÀ:
... self-administered internet-based survey of 10,138 adults with a reported history of high cholesterol and statin use. Of the respondents, 60% of former statin users (n = 1220) reported ever experiencing new or worsened muscle pain on a statin, in contrast to 25% of current users (n = 8918; P < .001). Former statin users reported stopping more statins because of muscle symptoms (mean ± standard deviation, 2.2 ± 1.7) compared with current users (mean 1.6 ± 1.5, P < .0001). For those with muscle-related symptoms while on a statin, participants reported that providers most often suggested switching to another statin (33.8%), stopping the statin (15.9%), continuing the statin with further monitoring of muscle symptoms (12.2%), reducing the statin dose (9.8%), or getting a blood test for signs of muscle damage (9.2%). A lower percentage were advised to add either vitamin D (7.0%) or coenzyme Q10 (5.8%), or to switch to nonstatin therapy (6.1%) or red yeast rice (2.6%). --- Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Îòêóäà ðàñòóò íîãè ó ïîâûøåííîãî èíòåðåñà ê âèòàìèíó Ä â ïîëíîé âåðñèè: Khayznikov M, et al. Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation. N Am J Med Sci. 2015;7:86–93. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ïåðåïèñêà: Statin Intolerance and Vitamin D Supplementation: Sunny, but a Few Clouds Remain… [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Statin Intolerance and Vitamin D Supplementation. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Atherosclerosis. 2017 Jan;256:125-127. Low serum vitamin D, statin associated muscle symptoms, vitamin D supplementation. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] À åñëè ñêðåñòèòü áóëüäîãà ñ íîñîðîãîì? Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: A randomized placebo-controlled trial. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#763
|
|||
|
|||
Æåñòü, ïî äðóãîìó íå ñêàæåøü
Self-Management of an Inferior ST-Segment Elevation Myocardial Infarction [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì |
#764
|
||||
|
||||
Êàêèõ-òî òðè ãîäà, è äâîéíàÿ òåðàïèÿ ïðè èøåìè÷åñêîì èíñóëüòå îôèöèàëüíî. Óðà!
À ïåíòîêñèôèëëèí çàïðåùåí - äàâíî ïîðà. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#765
|
||||
|
||||
Randomization to omega-3 fatty acid supplementation (eicosapentaenoic acid dose range, 226-1800 mg/d) had no significant associations with coronary heart disease death (rate ratio [RR], 0.93; 99% CI, 0.83-1.03; P = .05), nonfatal myocardial infarction (RR, 0.97; 99% CI, 0.87-1.08; P = .43) or any coronary heart disease events (RR, 0.96; 95% CI, 0.90-1.01; P = .12). Neither did randomization to omega-3 fatty acid supplementation have any significant associations with major vascular events (RR, 0.97; 95% CI, 0.93-1.01; P = .10), overall or in any subgroups, including subgroups composed of persons with prior coronary heart disease, diabetes, lipid levels greater than a given cutoff level, or statin use.
--- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks Meta-analysis of 10 Trials Involving 77 917 Individuals JAMA Cardiol. 2018;3(3):225-234. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |